Education
About Us
Working with TipRanks
Follow Us
Keymed Biosciences, Inc. (HK:2162)
:2162
RESEARCH TOOLSreports
2162 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$26.60 - HK$49.60
Previous CloseN/A
Volume918.50K
Average Volume (3M)2.52M
Market Cap
HK$10.13B
Enterprise ValueHK$6.84B
Total Cash (Recent Filing)¥851.03M
Total Debt (Recent Filing)¥418.71M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Sep 02, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding279,735,570
10 Day Avg. Volume3,577,577
30 Day Avg. Volume2,521,051
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)139.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$60.00Price Target Upside55.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Keymed Biosciences, Inc. News
PremiumCompany Announcements
Keymed Biosciences to Review Annual Results and Dividend
PremiumCompany Announcements
Keymed Biosciences Licenses CM355 to Prolium for Global Development
PremiumCompany Announcements
Keymed Biosciences Secures Licensing Deal for CM313PremiumCompany Announcements
Keymed Biosciences Gains NMPA Approval for Stapokibart
PremiumCompany Announcements
Keymed Biosciences Relocates Hong Kong Headquarters
PremiumCompany Announcements
Keymed Biosciences’ CM336 Shows Promise in Myeloma Study
PremiumCompany Announcements
Keymed Biosciences Expands Global Reach with CM336 Deal---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.28%
Mutual Funds
― Other Institutional Investors
95.06% Public Companies and
Individual Investors
2162 FAQ
What was Keymed Biosciences, Inc.’s price range in the past 12 months?
Keymed Biosciences, Inc. lowest stock price was HK$26.60 and its highest was HK$49.60 in the past 12 months.
What is Keymed Biosciences, Inc.’s market cap?
Keymed Biosciences, Inc.’s market cap is HK$10.13B.
When is Keymed Biosciences, Inc.’s upcoming earnings report date?
Keymed Biosciences, Inc.’s upcoming earnings report date is Sep 02, 2025 which is in 143 days.
How were Keymed Biosciences, Inc.’s earnings last quarter?
Keymed Biosciences, Inc. released its earnings results on Mar 24, 2025. The company reported -HK$0.737 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.737.
Is Keymed Biosciences, Inc. overvalued?
According to Wall Street analysts Keymed Biosciences, Inc.’s price is currently Undervalued.
Does Keymed Biosciences, Inc. pay dividends?
Keymed Biosciences, Inc. does not currently pay dividends.
What is Keymed Biosciences, Inc.’s EPS estimate?
Keymed Biosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Keymed Biosciences, Inc. have?
Keymed Biosciences, Inc. has 279,735,570 shares outstanding.
What happened to Keymed Biosciences, Inc.’s price movement after its last earnings report?
Keymed Biosciences, Inc. reported an EPS of -HK$0.737 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.524%.
Which hedge fund is a major shareholder of Keymed Biosciences, Inc.?
Currently, no hedge funds are holding shares in HK:2162
---
Keymed Biosciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$60.00 (55.04% Upside)
HK$60.00 (55.04% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.10%
12-Months-Change
Fundamentals
Return on Equity
-18.87%
Trailing 12-Months
Asset Growth
-6.24%
Trailing 12-Months
Company Description
Keymed Biosciences, Inc.
Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.
---
2162 Stock 12 Month Forecast
Average Price Target
HK$60.00
▲(55.04% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Viva Biotech Holdings
―
CanSino Biologics, Inc. Class H
―
Best Analysts Covering 2162
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+29.70%
reiterated a buy rating 3 months ago
Copying Wangbin Zhou's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +29.70% per trade.
---